CD274 and urinary bladder cancer: In recent years, the advent of immunotherapy, particularly programmed cell death protein 1 (PD-1) and programmed-death ligand 1 (PD-L1) inhibitors, has presented new therapeutic opportunities for patients with bladder cancer (2).